Journal ArticleDOI
Statin Induced Cholestatic Hepatitis: Confirmed on Re-Challenge
Reads0
Chats0
TLDR
A patient with statin-induced symptomatic cholestatic hepatitis that was confirmed on rechallenge is described.About:
This article is published in The American Journal of Gastroenterology.The article was published on 2006-09-01. It has received 5 citations till now.read more
Citations
More filters
Journal Article
Statins and Liver Injury
TL;DR: Clinical trials have shown that statin use has been associated with elevations in serum alanine aminotransferase (ALT) levels in approximately 3% of persons who take the drugs, while post hoc analysis from GREACE showed a reduction in cardiovascular events in patients with nonalcoholic fatty liver disease and coronary artery disease who were treated with atorvastatin.
Journal ArticleDOI
Atorvastatin alters the expression of genes related to bile acid metabolism and circadian clock in livers of mice
TL;DR: Examination of the effects of atorvastatin on hepatic gene expression related to bile acid metabolism and homeostasis, as well as the expression of circadian clock genes in livers of mice found that repeated administration affects bile Acid metabolism and markedly increases theexpression of the bileacid synthesis rate-limiting enzyme gene Cyp7a1.
Journal ArticleDOI
Statin-induced Liver Injury Patterns: A Clinical Review
TL;DR: Current literature supports statin induced liver injury presenting in either hepatocellular or cholestatic patterns, though with the former being the prevailing pattern of injury.
Journal ArticleDOI
High-Dose Statin Associated with Rhabdomyolysis, Acute Kidney Injury, Cholestatic Liver Injury, and Thrombocytopenia
TL;DR: Using statins for primary and secondary prevention of cardiovascular diseases has become commonplace and lipid-lowering therapies have become more intense in compliance with the more aggressive targets set by the trials demonstrating their safety and efficacy in high-risk patients.
Journal ArticleDOI
Statin treatment in patients with elevated liver enzymes: Pitch to proceed
TL;DR: The improvement in ALT with statin therapy in the PITCH study is small but encouraging, consistent with a controlled long-term histopathologic study in which long- term statin treatment improved liver histology with regression of steatosis.
References
More filters
Journal ArticleDOI
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
TL;DR: Growing evidence suggests that nonalcoholic fatty liver disease is associated with an increased risk of cardiovascular disease beyond that conferred by established risk factors.
Journal ArticleDOI
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors.
TL;DR: The discovery and development of lovastatin — the first approved inhibitor of HMG-CoA reductase — and the clinical trials that have provided the evidence for the ability of drugs in this class to reduce the morbidity and mortality associated with cardiovascular disease are described.
Journal ArticleDOI
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis
Vasilios G. Athyros,Konstantinos Tziomalos,Thomas D. Gossios,Theodora Griva,Panagiotis Anagnostis,Konstantinos Kargiotis,Efstathios D. Pagourelias,Eleni Theocharidou,Asterios Karagiannis,Dimitri P. Mikhailidis +9 more
TL;DR: Statin treatment is safe and can improve liver tests and reduce cardiovascular morbidity in patients with mild-to-moderately abnormal liver tests that are potentially attributable to non-alcoholic fatty liver disease.
Journal ArticleDOI
Risks Associated With Statin Therapy A Systematic Overview of Randomized Clinical Trials
Amir Kashani,Christopher O. Phillips,JoAnne M. Foody,Yongfei Wang,Sandeep Mangalmurti,Dennis T. Ko,Harlan M. Krumholz +6 more
TL;DR: This paper performed a systematic overview of randomized statin trials to quantify the risks of musculoskeletal, renal, and hepatic complications associated with therapy and found that statin therapy did not result in significant absolute increases in risks of myalgias (risk difference/1000 patients [RD], 2.7; 95% CI, −3.2 to 8.7), creatine kinase el...
Journal ArticleDOI
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity
Naga Chalasani,Hisham Aljadhey,Joe Kesterson,Michael D. Murray,Michael D. Murray,Stephen D. Hall +5 more
TL;DR: The data suggest that individuals with elevated baseline liver enzymes do not have higher risk for hepatotoxicity from statins.